CHF5993

· Chiesi Farmaceutici S.p.A.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for CHF5993, covering 2021-04-01 to 2023-03-24. Get the full timeline:

Most recent: Clinical Trial Update: CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD [Phase 4]